Gordon Crofoot

3.2k total citations
27 papers, 981 citations indexed

About

Gordon Crofoot is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Gordon Crofoot has authored 27 papers receiving a total of 981 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Infectious Diseases, 19 papers in Virology and 12 papers in Emergency Medicine. Recurrent topics in Gordon Crofoot's work include HIV/AIDS drug development and treatment (25 papers), HIV Research and Treatment (19 papers) and HIV-related health complications and treatments (12 papers). Gordon Crofoot is often cited by papers focused on HIV/AIDS drug development and treatment (25 papers), HIV Research and Treatment (19 papers) and HIV-related health complications and treatments (12 papers). Gordon Crofoot collaborates with scholars based in United States, United Kingdom and France. Gordon Crofoot's co-authors include Andrew Cheng, Joseph M. Custodio, Paul Benson, Hal Martin, Scott McCallister, Edwin DeJesus, Anthony Mills, Moti Ramgopal, Joseph Gathe and Marshall W. Fordyce and has published in prestigious journals such as Clinical Infectious Diseases, The Journal of Infectious Diseases and AIDS.

In The Last Decade

Gordon Crofoot

26 papers receiving 961 citations

Peers

Countries citing papers authored by Gordon Crofoot

Since Specialization

Citations

This map shows the geographic impact of Gordon Crofoot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gordon Crofoot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gordon Crofoot more than expected).

Fields of papers citing papers by Gordon Crofoot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gordon Crofoot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gordon Crofoot. The network helps show where Gordon Crofoot may publish in the future.

Co-authorship network of co-authors of Gordon Crofoot

This figure shows the co-authorship network connecting the top 25 collaborators of Gordon Crofoot. A scholar is included among the top collaborators of Gordon Crofoot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gordon Crofoot. Gordon Crofoot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Final efficacy and safety of twice-yearly subcutaneous lenacapavir in treatment-naive people with HIV 2025 ·AIDS ·Debbie Hagins, Mezgebe Berhe, Gordon Crofoot, Moti Ramgopal, James J. Sims, Cheryl McDonald, Peter Ruane, William E. Sanchez, Anita Scribner, Paul Benson, Shanyu Liu, Laurie A. VanderVeen, Hadas Dvory‐Sobol, Martin S. Rhee, Samir K. Gupta	0
2	Improvements in Patient-Reported Outcomes After 12 Months of Maintenance Therapy With Cabotegravir + Rilpivirine Long-Acting Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide in the Phase 3b SOLAR Study 2024 ·AIDS and Behavior ·Cristina Mussini, Charles Cazanave, Eisuke Adachi, (unknown), Marta Montero, Gordon Crofoot, Vasiliki Chounta, (unknown), Kenneth Sutton, Denise Sutherland‐Phillips, (unknown), (unknown), (unknown), Patricia Rios, Ronald D’Amico, William Spreen, Jean van Wyk	3
3	Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study 2024 ·The Lancet HIV ·Joseph J. Eron, Susan J. Little, Gordon Crofoot, Paul Cook, Peter Ruane, Dushyantha Jayaweera, Laurie A. VanderVeen, Edwin DeJesus, (unknown), Anthony Mills, Hailin Huang, Sarah Waldman, Moti Ramgopal, Linda Gorgos, Sean E Collins, Jared M. Baeten, Marina Caskey	24
4	Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial 2022 ·The Lancet HIV ·Samir K. Gupta, Mezgebe Berhe, Gordon Crofoot, Paul Benson, Moti Ramgopal, James J. Sims, Cheryl McDonald, Peter Ruane, (unknown), Anita Scribner, Shanyu Liu, Laurie A. VanderVeen, Hadas Dvory‐Sobol, Martin S. Rhee, Jared M. Baeten, Ellen Koenig	65
5	887. High Rates of Virologic Suppression Achieved in HIV-1–Infected Adults Rapidly Starting Antiretroviral Therapy (ART) with the Single-Tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) 800/150/200/10 mg Regardless of Baseline Disease Characteristics: Week 48 Subgroup Analyses From the Phase 3 DIAMOND Trial 2019 ·Open Forum Infectious Diseases ·Gregory Huhn, Moti Ramgopal, Gordon Crofoot, Joseph Gathe, (unknown), (unknown), (unknown), Donghan Luo, (unknown)	1
6	Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide 2018 ·AIDS ·Paul E. Sax, Edwin DeJesus, Gordon Crofoot, Douglas Ward, Paul Benson, Robin Dretler, Anthony Mills, Cynthia Brinson, Xuelian Wei, Sean E Collins, Andrew Cheng	7
7	Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial 2018 ·The Lancet HIV ·Eric S. Daar, Edwin DeJesus, Peter Ruane, Gordon Crofoot, Godson Oguchi, Catherine Creticos, Jürgen K. Rockstroh, Jean‐Michel Molina, Ellen Koenig, Ya-Pei Liu, Joseph M. Custodio, Kristen Andreatta, Hiba Graham, Andrew Cheng, Hal Martin, Erin Quirk	117
8	Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial 2018 ·The Lancet HIV ·Alan Winston, Frank A. Post, Edwin DeJesus, Daniel Podzamczer, Giovanni Di Perri, Vicente Estrada, François Raffi, Peter Ruane, Paula Peyrani, Gordon Crofoot, Patrick Mallon, Francesco Castelli, Mingjin Yan, Stephanie Cox, Moupali Das, Andrew Cheng, Martin S. Rhee	20
9	Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study 2017 ·The Lancet HIV ·Edwin DeJesus, Moti Ramgopal, Gordon Crofoot, Peter Ruane, Anthony LaMarca, Anthony Mills, Claudia Martorell, (unknown), Hans‐Jürgen Stellbrink, Jean‐Michel Molina, Frank A. Post, Ignacio Valero, Danielle Porter, Ya-Pei Liu, Andrew Cheng, Erin Quirk, Devi SenGupta, Huyen Cao	37
10	Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial 2017 ·The Lancet HIV ·Paul E. Sax, Edwin DeJesus, Gordon Crofoot, Douglas Ward, Paul Benson, Robin Dretler, Anthony Mills, Cynthia Brinson, (unknown), Xuelian Wei, Kirsten White, Andrew Cheng, Hal Martin, Erin Quirk	72
11	Phase 3 Randomized, Controlled Trial of Switching to Fixed-dose Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Boosted Protease Inhibitor-based Regimens in Virologically Suppressed Adults: Week 48 Results 2017 ·Open Forum Infectious Diseases ·Eric S. Daar, Edwin DeJesus, Peter Ruane, Gordon Crofoot, Godson Oguchi, Catherine Creticos, Jürgen K. Rockstroh, Jean‐Michel Molina, Ellen Koenig, Ya-Pei Liu, Kristen Andreatta, Hiba Graham, Andrew Cheng, Hal Martin, Erin Quirk	4
12	A Randomized Trial of Bictegravir or Dolutegravir with Emtricitabine and Tenofovir Alafenamide (F/TAF) Followed by Open Label Switch to Bictegravir/F/TAF Fixed Dose Combination 2017 ·Open Forum Infectious Diseases ·Paul E. Sax, Edwin DeJesus, Gordon Crofoot, Douglas Ward, Paul Benson, (unknown), Kirsten White, Sean E Collins, Hal Martin, Andrew Cheng, Erin Quirk	1
13	Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study 2016 ·LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) ·Anton Pozniak, José Ramón Arribas, Joseph Gathe, Samir K. Gupta, Frank A. Post, (unknown), Anchalee Avihingsanon, Gordon Crofoot, Paul Benson, Kenneth Lichtenstein, Moti Ramgopal, Ploenchan Chetchotisakd, Joseph M. Custodio, Michael E. Abram, Xuelian Wei, Andrew Cheng, Scott McCallister, Devi SenGupta, Marshall W. Fordyce	12
14	P031: Tenofovir alafenamide in a single-tablet regimen in initial HIV-1 therapy 2015 ·Journal of the International AIDS Society ·Edwin DeJesus, (unknown), Anton Pozniak, Melanie Thompson, Daniel Podzamczer, Jean‐Michel Molina, Gordon Crofoot, Christian Callebaut, Hal Martin, (unknown), Scott McCallister	9
15	Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment 2015 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Anton Pozniak, José Ramón Arribas, Joseph Gathe, Samir K. Gupta, Frank A. Post, (unknown), Anchalee Avihingsanon, Gordon Crofoot, Paul Benson, Kenneth Lichtenstein, Moti Ramgopal, Ploenchan Chetchotisakd, Joseph M. Custodio, Michael E. Abram, Xuelian Wei, Andrew Cheng, Scott McCallister, Devi SenGupta, Marshall W. Fordyce	158
16	Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy 2015 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Anthony Mills, Gordon Crofoot, Cheryl McDonald, Peter Shalit, Jason Flamm, Joseph Gathe, Anita Scribner, David Shamblaw, Michael S. Saag, Huyen Cao, Hal Martin, Moupali Das, Anne Thomas, Hui C. Liu, Mingjin Yan, Christian Callebaut, Joseph M. Custodio, Andrew Cheng, Scott McCallister	121
17	Switching from a Tenofovir Disoproxil Fumarate (TDF) to a Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen (STR): Week 48 Data in HIV-1-Infected Virologically Suppressed Adults 2015 ·Open Forum Infectious Diseases ·Melanie Thompson, Javier O Morales-Ramirez, Cheryl McDonald, Anita Rachlis, Christian Hoffmann, Adriano Lazzarin, Gordon Crofoot, Andrew Plummer, Ya-Pei Liu, Andrew Cheng, Scott McCallister	1
18	Switching From Twice-Daily Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine to Once-Daily Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed, HIV-1–Infected Subjects: 48 Weeks Data 2014 ·HIV Clinical Trials ·Anthony Mills, Gordon Crofoot, Roberto Ortiz, Bruce Rashbaum, William Towner, Derek Ward, Cynthia Brinson, Rohan Kulkarni, (unknown), Ramin Ebrahimi, H. Cao, Andrew Cheng, Javier Szwarcberg	17
19	Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial 2014 ·AIDS Research and Therapy ·Karen T. Tashima, Gordon Crofoot, Frank Tomaka, Thomas N. Kakuda, (unknown), Tom Van de Casteele, Magda Opsomer, (unknown), Nicolas Margot, Joseph M. Custodio, Marshall W. Fordyce, Javier Szwarcberg	48
20	Antibody to Capsular Polysaccharides of Streptococcus pneumoniae after Vaccination of Human Immunodeficiency Virus-Infected Subjects with 23-Valent Pneumococcal Vaccine 1992 ·The Journal of Infectious Diseases ·Maria C. Rodriguez‐Barradas, D. M. Musher, (unknown), Christine E. Lacke, J. E. Groover, David Watson, R E Baughn, T. R. Cate, Gordon Crofoot	113

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact